Diffuse pulmonary ossification in Idiopathic Pulmonary Fibrosis: Forli 10-year experience

N. Muhammad (Bandar Baru Bangi, Selangor, Malaysia)

Source: International Congress 2017 – The wide spectrum of ILDs
Session: The wide spectrum of ILDs
Session type: Poster Discussion
Number: 2950
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Muhammad (Bandar Baru Bangi, Selangor, Malaysia). Diffuse pulmonary ossification in Idiopathic Pulmonary Fibrosis: Forli 10-year experience. 2950

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis?
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020


Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014


Treatment of Idiopathic Pulmonary Fibrosis
Source: Guideline 2015
Year: 2015

Idiopathic Pulmonary Fibrosis: mortality trends in Chile
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019


Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis
Source: International Congress 2019 – M-health/e-health I
Year: 2019


Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014


Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016
Year: 2017




Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
Source: International Congress 2014 – ILDs 1
Year: 2014


IPF - Idiopathic Pulmonary Fibrosis
Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152
Year: 2019



Epidemiology of Idiopathic Pulmonary Fibrosis in Australia
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Course 2019 - Interstitial Lung Diseases
Year: 2018

Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Course 2019 - Interstitial Lung Diseases
Year: 2019


Idiopathic Pulmonary Fibrosis (IPF)
Source: ERS Courses: Interstitial Lung Diseases
Year: 2019


Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014


Impact of depression on patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases
Year: 2017

Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014


Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014


Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD
Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions
Year: 2013